In the L-enantiomer form, WX-UK1 added at nano-molar concentrations to breast cancer cells, inhibited the proteolytic activity of uPA, plasmin and thrombin in a dose-dependent manner. The gene discussed is PLAU; the disease is breast carcinoma.